Featured Products 
Highlights
Welcome to Clinical Cell Culture | C3 |
Clinical Cell Culture | C3 | is a publicly listed company established to commercialise a number of tissue engineered products for the treatment of skin defects using autologous cell replacement.
C3 uses unique tissue engineering processes to grow skin cells from a small sample of the patient’s own skin. The skin is then applied to the wound to ensure increased healing rates with minimal scarring.
Our proprietary skin replacement products, including CellSpray® and ReCell® offer clinicians a range of options for the treatment of burns, scars, chronic wounds, cosmetic surgery procedures and other types of epidermal trauma.
Merger Completion
Clinical Cell Culture Ltd (C3, ASX: CCE) and Visiomed Group Ltd (“Visiomed”) are pleased to announce that the Federal Court in Perth has today given final approval to the schemes of arrangement between the two companies.
www.visiomed.com.au
